Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jan;71(1):150–154. doi: 10.1038/bjc.1995.31

Pathological and biological features of mammographically detected invasive breast carcinomas.

R Rajakariar 1, R A Walker 1
PMCID: PMC2033448  PMID: 7819032

Abstract

The pathological and biological features of a consecutive series of impalpable invasive breast carcinoma, detected by mammography in the prevalent round of the breast screening programme, have been compared with a clinically presenting group of carcinomas in age-matched patients. There was a significantly higher prevalence of tubular carcinomas as well-differentiated infiltrating ductal carcinomas in the mammographically detected group, and a lower prevalence of poorly differentiated infiltrating ductal carcinomas. Lymph node metastasis was found in 6.5% of the impalpable group compared with 53% of the clinical group. The prevalence of oestrogen receptor was much higher in the impalpable group (96%) than in the control group (67%), although there were no significant differences for progesterone receptor. The prevalence of pS2 was also much higher in the impalpable group, as was cathepsin D. This finding is surprising in view of the reported relationship between cathepsin D and poorer survival. p53 and c-erb-2 proteins were detectable in fewer impalpable carcinomas. The mean MIBI (Ki-67) index was lower in the impalpable group (11.6) than in the clinical group (15.25). Within the mammographically detected group there was a significant difference in the MIBI index between tubular carcinomas and the different grades of infiltrating ductal carcinomas, with a wide range in each category but no association with size. The impalpable carcinomas detected by mammography differ from clinically presenting carcinomas in many ways, raising the question of whether a proportion or all would progress (dedifferentiate) with time.

Full text

PDF
150

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Molina R., Tandon A. K., Schnitt S. J., Gilchrist K. W., Osborne C. K., Tormey D. C., McGuire W. L. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep;23(9):974–979. doi: 10.1016/0046-8177(92)90257-4. [DOI] [PubMed] [Google Scholar]
  2. Anderson T. J., Lamb J., Alexander F., Lutz W., Chetty U., Forrest A. P., Kirkpatrick A., Muir B., Roberts M. M., Huggins A. Comparative pathology of prevalent and incident cancers detected by breast screening. Edinburgh Breast Screening Project. Lancet. 1986 Mar 8;1(8480):519–523. doi: 10.1016/s0140-6736(86)90882-2. [DOI] [PubMed] [Google Scholar]
  3. Anderson T. J., Lamb J., Donnan P., Alexander F. E., Huggins A., Muir B. B., Kirkpatrick A. E., Chetty U., Hepburn W., Smith A. Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer. 1991 Jul;64(1):108–113. doi: 10.1038/bjc.1991.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnes D. M., Dublin E. A., Fisher C. J., Levison D. A., Millis R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993 May;24(5):469–476. doi: 10.1016/0046-8177(93)90158-d. [DOI] [PubMed] [Google Scholar]
  5. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  6. Cowan W. K., Angus B., Henry J., Corbett I. P., Reid W. A., Horne C. H. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer. 1991 Oct;64(4):780–784. doi: 10.1038/bjc.1991.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ellis I. O., Galea M., Broughton N., Locker A., Blamey R. W., Elston C. W. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992 Jun;20(6):479–489. doi: 10.1111/j.1365-2559.1992.tb01032.x. [DOI] [PubMed] [Google Scholar]
  8. Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–410. doi: 10.1111/j.1365-2559.1991.tb00229.x. [DOI] [PubMed] [Google Scholar]
  9. Foekens J. A., Rio M. C., Seguin P., van Putten W. L., Fauque J., Nap M., Klijn J. G., Chambon P. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 1990 Jul 1;50(13):3832–3837. [PubMed] [Google Scholar]
  10. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  11. Henry J. A., McCarthy A. L., Angus B., Westley B. R., May F. E., Nicholson S., Cairns J., Harris A. L., Horne C. H. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990 Jan 15;65(2):265–271. doi: 10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  12. Henry J. A., Piggott N. H., Mallick U. K., Nicholson S., Farndon J. R., Westley B. R., May F. E. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer. 1991 Apr;63(4):615–622. doi: 10.1038/bjc.1991.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klemi P. J., Joensuu H., Toikkanen S., Tuominen J., Räsänen O., Tyrkkö J., Parvinen I. Aggressiveness of breast cancers found with and without screening. BMJ. 1992 Feb 22;304(6825):467–469. doi: 10.1136/bmj.304.6825.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McClelland R. A., Wilson D., Leake R., Finlay P., Nicholson R. I. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. Eur J Cancer. 1991;27(6):711–715. doi: 10.1016/0277-5379(91)90171-9. [DOI] [PubMed] [Google Scholar]
  15. McKinney C. D., Frierson H. F., Jr, Fechner R. E., Wilhelm M. C., Edge S. B. Pathologic findings in nonpalpable invasive breast cancer. Am J Surg Pathol. 1992 Jan;16(1):33–36. doi: 10.1097/00000478-199201000-00005. [DOI] [PubMed] [Google Scholar]
  16. Poller D. N., Hutchings C. E., Galea M., Bell J. A., Nicholson R. A., Elston C. W., Blamey R. W., Ellis I. O. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer. 1992 Sep;66(3):583–588. doi: 10.1038/bjc.1992.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pujol P., Maudelonde T., Daures J. P., Rouanet P., Brouillet J. P., Pujol H., Rochefort H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer. 1993 Mar 15;71(6):2006–2012. doi: 10.1002/1097-0142(19930315)71:6<2006::aid-cncr2820710614>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  18. Rasmussen B. B., Rose C., Thorpe S. M., Hou-Jensen K., Daehnfeldt J. L., Palshof T. Histopathological characteristics and oestrogen receptor content in primary breast carcinoma. Virchows Arch A Pathol Anat Histol. 1981;390(3):347–351. doi: 10.1007/BF00496564. [DOI] [PubMed] [Google Scholar]
  19. Roberts M. M., Alexander F. E., Anderson T. J., Chetty U., Donnan P. T., Forrest P., Hepburn W., Huggins A., Kirkpatrick A. E., Lamb J. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. 1990 Feb 3;335(8684):241–246. doi: 10.1016/0140-6736(90)90066-e. [DOI] [PubMed] [Google Scholar]
  20. Shapiro S., Venet W., Strax P., Venet L., Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. Natl Cancer Inst Monogr. 1985 May;67:65–74. [PubMed] [Google Scholar]
  21. Soomro S., Shousha S., Sinnett H. D. Oestrogen and progesterone receptors in screen-detected breast carcinoma: an immunohistological study using paraffin sections. Histopathology. 1992 Dec;21(6):543–547. doi: 10.1111/j.1365-2559.1992.tb00442.x. [DOI] [PubMed] [Google Scholar]
  22. Spyratos F., Maudelonde T., Brouillet J. P., Brunet M., Defrenne A., Andrieu C., Hacene K., Desplaces A., Rouëssé J., Rochefort H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989 Nov 11;2(8672):1115–1118. doi: 10.1016/s0140-6736(89)91487-6. [DOI] [PubMed] [Google Scholar]
  23. Stål O., Brisfors A., Carstensen J., Ferraud L., Hatschek T., Nordenskjöld B. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. The South-East Sweden Breast Cancer Group. Int J Cancer. 1992 Apr 22;51(1):28–33. doi: 10.1002/ijc.2910510106. [DOI] [PubMed] [Google Scholar]
  24. Tabár L., Fagerberg C. J., Gad A., Baldetorp L., Holmberg L. H., Gröntoft O., Ljungquist U., Lundström B., Månson J. C., Eklund G. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13;1(8433):829–832. doi: 10.1016/s0140-6736(85)92204-4. [DOI] [PubMed] [Google Scholar]
  25. Tabár L., Fagerberg G., Day N. E., Duffy S. W., Kitchin R. M. Breast cancer treatment and natural history: new insights from results of screening. Lancet. 1992 Feb 15;339(8790):412–414. doi: 10.1016/0140-6736(92)90090-p. [DOI] [PubMed] [Google Scholar]
  26. Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990 Feb 1;322(5):297–302. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
  27. Thor A. D., Koerner F. C., Edgerton S. M., Wood W. C., Stracher M. A., Schwartz L. H. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat. 1992;21(2):111–119. doi: 10.1007/BF01836957. [DOI] [PubMed] [Google Scholar]
  28. Verbeek A. L., Hendriks J. H., Holland R., Mravunac M., Sturmans F., Day N. E. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984 Jun 2;1(8388):1222–1224. doi: 10.1016/s0140-6736(84)91703-3. [DOI] [PubMed] [Google Scholar]
  29. Walker R. A., Dearing S. J., Lane D. P., Varley J. M. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol. 1991 Nov;165(3):203–211. doi: 10.1002/path.1711650303. [DOI] [PubMed] [Google Scholar]
  30. Walker R. A., Gullick W. J., Varley J. M. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer. 1989 Sep;60(3):426–429. doi: 10.1038/bjc.1989.299. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES